Physician profile
Thomas John
NPI 1770577884
$16,713.63
in general payments reported to CMS, 2019-2025
50 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,621 · 2020: $1,816 · 2021: $2,563 · 2022: $2,635 · 2023: $2,776 · 2024: $2,669 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,978 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,978.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,569.37 | 2019-2025 | |
| Pfizer INC. | $1,712.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,626.39 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,089.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,038.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,018.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $925.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.36 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $572.87 | 2022-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $565.51 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.19 | 2020-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $381.76 | 2023-2025 | Freestyle Libre 3, Merlin@Home |
| Merck Sharp & Dohme LLC | $367.52 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $343.89 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $312.34 | 2019-2024 | Livalo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.